Researchers in Japan have developed a lipocalin-based drug delivery system that dramatically increases the solubility of the anticancer drug paclitaxel and enhances tumour suppression in a breast ...

Anticancer drug discovery has evolved into a multidisciplinary endeavour that integrates medicinal chemistry, biological evaluation and in silico studies to design agents with enhanced efficacy and ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers. BRCA2, a crucial player in the body's DNA repair system, aids in repairing damaged DNA.

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy.

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy Many drugs in development continue to follow the historical drug development ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Researchers have developed a human intestinal cell model that closely mimics the structure and function of the human gut, enabling more precise prediction of drug-induced gastrointestinal toxicity ...